| +0.11 / +0.70%|
The 3 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 60.00, with a high estimate of 62.00 and a low estimate of 49.00. The median estimate represents a +277.12% increase from the last price of 15.91.
The current consensus among 3 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.